Serum nitrite/nitrate and arginase levels in patients with allergic rhinitis.

Nitric oxide (NO) plays an important role in the regulation of upper respiratory function. Patients with untreated allergic rhinitis (AR) have an increased level of NO in the nasal cavity compared to normal individuals. We aimed to investigate serum levels of arginase and NO metabolites nitrite/nitrate in patients with AR during the symptomatic period. The patient and control groups consisted of 14 males and 12 females (mean age: 29, range: 20-40 years), and 10 males and 10 females (mean age: 27, range: 22-38 years), respectively. Nitrite/nitrate levels were 0.98 +/- 0.33 ng/ml in the patients with AR, and 0.78 +/- 0.26 ng/ml in the control group (p = 0.03). Arginase levels were 28.8 +/- 14.1 ng/ml in the patients with AR, and 20.8 +/- 13.5 ng/ml in the control group. The difference between the groups was statistically insignificant (p = 0.24). Our results support the view that NO plays an important role in the pathogenesis of AR, and NO metabolites may be used as a marker for monitoring the disease activity and therapy.

Cyanoacrylate adhesive provides efficient local drug delivery.

Biodegradable drug delivery systems have advanced treatment of a wide spectrum of musculoskeletal problems. However, their lack of availability and cost can restrict use. To find an easily available and inexpensive biodegradable implant, we tested a widely used tissue adhesive, n-butyl-2-cyanoacrylate, as a drug-trapping material. We tested vancomycin with commercially available absorbable gelatin-sponge pieces as the scaffold. We evaluated the in vitro and in vivo drug release profiles and in vivo inflammatory response. A mouse muscle pouch model was used for in vivo evaluations. The released vancomycin level was measured by fluorescence polarization immunoassay technique, and a leukocyte count-based grading system was used to evaluate inflammatory response. Our findings suggest the proposed implant provides effective drug release for as much as 42 days in vitro and 14 days in vivo. The presence of n-butyl-2-cyanoacrylate led to a local inflammatory response which decreased after 3 weeks in the group with less adhesive. These results showed that n-butyl-2-cyanoacrylate could efficiently trap and slowly release a drug when used in the structure of a biodegradable local drug delivery device.

Leukotriene C4 synthase A-444C gene polymorphism in patients with allergic rhinitis.

OBJECTIVE: To determine the frequency of leukotriene C4 synthase A-444C polymorphism in allergic rhinitis patients. STUDY DESIGN AND SETTING: A prospective, randomized, case-controlled study. Blood samples were obtained from 85 patients with allergic rhinitis and 95 healthy individuals. After the extraction of DNA from the blood samples, the leukotriene C4 synthase A-444C polymorphism was studied by a real-time polymerase chain reaction method. RESULTS: The AC and CC genotype frequencies were statistically higher in the study group (P = 0.048 and P = 0.037, respectively). In addition, the AC polymorphism carried an increased risk of developing allergic rhinitis (odds ratio = 2.18, 95% confidence interval, 1.173-4.053, P = 0.014). CONCLUSION: The C allele of the leukotriene C4 synthase gene increases the risk of developing allergic rhinitis. SIGNIFICANCE: The leukotriene C4 synthase A-444C gene polymorphism is important in susceptibility to allergic rhinitis and this is the first study of this gene polymorphism in allergic rhinitis. EBM RATING: B-3b.